Clinical Trials Logo
  1. Home
  2. Pulmonary Arterial Hypertension
  3. NCT01553721
  4. Details
NCT01553721 Clinical Trial

Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

Pulmonary Arterial Hypertension Clinical Trial

Official title:
A Placebo-controlled, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01553721
Other study ID # DA8159_PAH_II
Secondary ID
Status Completed
Phase Phase 2
First received January 1, 2012
Last updated April 15, 2016
Start date August 2011
Est. completion date March 2015

Study information
Verified date April 2016
Source Dong-A ST Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority South Korea: Ministry of Food and Drug Safety
Study type Interventional

Clinical Trial Summary

This is a placebo-controlled, double-blind, phase II clinical study to evaluate the efficacy and safety of Udenafil in patient with Pulmonary Arterial Hypertension(PAH).

Recruitment information / eligibility
Status Completed
Enrollment 63
Est. completion date March 2015
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

• Subjects aged 18 and over who have any of the following diseases

- primary Pulmonary Arterial Hypertension

- secondary Pulmonary Arterial Hypertension caused by connective tissue disease

- [Phase IIb] Pulmonary Arterial Hypertension caused by congenital heart disease(including Eisenmenger syndrome)

Exclusion Criteria:

- Subjects with pulmonary arterial hypertension caused by any etiology other than those specified in the inclusion criteria

- BMI(Body Mass Index) < 18.5kg/m2

- Subjects with hypotension(SBP/DBP<90/50mmHg) or uncontrolled hypertension(SBP/DBP>170/100mmHg)

- Creatinine clearance = 30mL/min

- History of non-arteritic anterior ischemic optic neuropathy(NAION)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• udenafil
Phase IIa - Udenafil Dose 1, Dose 2(Single dose) Phase IIb - Udenafil(BID)
• placebo
Phase IIa - placebo Phase IIb - placebo

Locations
Country Name City State
Korea, Republic of Chungbook national University Hospital Chung-ju
Korea, Republic of Chungnam National University Hospital Daejeon
Korea, Republic of Chonnam National University Hospital Gwang-ju
Korea, Republic of Pusan national University Hospital Pusan
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Samsung Medical Center Seoul Gangnam-Gu, Irwon-Dong 50
Korea, Republic of Seoul National University Hospital Seoul Chongno-gu, 28 Yongon-dong
Korea, Republic of The catholic univ. of korea Seoul ST. MARY's hospital Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System Special City of Seoul Seodaemungu, 250 Seonsanno

Sponsors (1)
Lead Sponsor Collaborator
Dong-A ST Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Phase IIa - Pulmonary vascular resistance index(PVRI) 4 hours No
Primary Phase IIb - 6-minute walk distance 16weeks No
See also
  Status Clinical Trial Phase
Completed NCT04076241 - Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension N/A
Completed NCT05521113 - Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension
Recruiting NCT04972656 - Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension N/A
Completed NCT04908397 - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension Phase 1
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT01959815 - Novel Screening Strategies for Scleroderma PAH
Recruiting NCT04266197 - Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study Phase 2
Active, not recruiting NCT06092424 - High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA) N/A
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Terminated NCT02060487 - Effects of Oral Sildenafil on Mortality in Adults With PAH Phase 4
Terminated NCT02253394 - The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study Phase 4
Withdrawn NCT02958358 - FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan N/A
Terminated NCT01953965 - Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI. Phase 2
Not yet recruiting NCT01649739 - Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost Phase 4
Unknown status NCT01712997 - Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients Phase 3
Withdrawn NCT01723371 - Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children Phase 1/Phase 2
Completed NCT01548950 - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension N/A
Completed NCT01165047 - Nitric Oxide, GeNO Nitrosyl Delivery System Phase 2
Completed NCT00902174 - Imatinib (QTI571) in Pulmonary Arterial Hypertension Phase 3
Completed NCT00963027 - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil Phase 1